Mizuho cuts BioXcel to neutral, cites reduced expectations for lead drug (BTAI)
juststock Mizuho downgraded BioXcel Therapeutics (NASDAQ:BTAI) to neutral and slashed its price target in the wake of the company’s Q2…
juststock Mizuho downgraded BioXcel Therapeutics (NASDAQ:BTAI) to neutral and slashed its price target in the wake of the company’s Q2…